Rarity Bioscience

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Foresight Diagnostics foresight-dx.comDirect competitorBoth offer ultra-sensitive ctDNA liquid biopsy mutation detection assays for research and clinical applications.
• Enumera Molecular enumeramolecular.comDirect competitorBoth provide platforms and assays for highly sensitive liquid biopsy and complex molecular diagnostics.
• AccuraGen, Inc. accuragen.comDirect competitorBoth develop liquid-biopsy technologies to detect and monitor cancer using circulating tumor DNA.
• mDETECT mdetect-inc.comDirect competitorBoth commercialize highly sensitive blood-based assays to monitor cancer via circulating tumor DNA signals.
• Delfi Diagnostics delfidiagnostics.comPartial overlapBoth focus on blood-based DNA liquid biopsy for early cancer detection, though using different technical approaches.
• Adela adelabio.comPartial overlapBoth support blood-based tests for cancer detection and MRD monitoring from circulating DNA.
• Nucleix nucleix.comPartial overlapBoth work on non-invasive ctDNA liquid biopsies for cancer detection and monitoring.
• Mercy BioAnalytics mercybio.comPartial overlapBoth are developing blood-based liquid biopsy tests for early-stage cancer detection.